PARPi Responsive Biomarker Discovery Service

Poly (ADP-ribose) polymerase inhibitors (PARPis) mark a major advancement in cancer treatment. As cancer genomics progresses, discovering biomarkers that predict patient responses to PARPis is essential. Such biomarkers enhance our understanding of drug efficacy and support personalized medicine approaches. Alfa Cytology offers comprehensive PARPi responsive biomarker discovery services for our clients.

Introduction to PARPi Responsive Biomarker

PARPis exploit the principle of synthetic lethality, selectively targeting cancer cells while sparing normal cells. As the landscape of cancer genomics evolves, the discovery of biomarkers that predict patient response to PARPis becomes increasingly crucial. Biomarkers not only enhance the understanding of drug efficacy but also facilitate personalized medicine approaches.

Fig. 1 Identification of potential biomarkers for PARP inhibitors (PARPis) using cancer genome data. (Dong Q., et al. 2021)

Our Services

At Alfa Cytology, we offer comprehensive PARPi responsive biomarker discovery services designed to support oncological research and clinical applications. Identifying predictive biomarkers is critical to PARP drug development. By combining multiple histological approaches, quantitative analysis protocols, and computational methods for data processing and statistical analysis, we help drug developers develop biomarker identification strategies to help drive the commercial success of their drugs.

Advanced Genomic Screening

Our team employs state-of-the-art genomic screening techniques to profile cancer cell lines and primary tumor samples. By leveraging CRISPR/Cas9 and RNAi technologies, we can systematically knock down or knockout specific genes to observe changes in cell viability in response to various PARPis.

Pharmacogenomic Data Analysis

In addition to genome editing, we perform in-depth analyses of pharmacogenomic datasets to uncover correlations between genetic mutations and drug response. By integrating data from resources such as the Genomics of Drug Sensitivity in Cancer (GDSC) and The Cancer Genome Atlas (TCGA), we can validate our findings and ensure their clinical relevance.

Our Advantages

Customized Service to Meet Customers
Perfect and Advanced Research Platform

Scientific and Rigorous Teamwork
Efficient and Perfect After-sales Service

Recognizing that each research project has unique requirements, Alfa Cytology offers customizable biomarker discovery solutions. Whether you are investigating specific cancer types or exploring novel combinations of PARPis with other therapeutic agents, our team can tailor our services to meet your specific needs. To learn more about our PARPi responsive biomarker discovery services or to discuss your specific research needs, please reach out to our expert team at Alfa Cytology.

Reference

Dong Q., Liu M., and et al. Revealing biomarkers associated with PARP inhibitors based on genetic interactions in cancer genome. Comput Struct Biotechnol J. 2021, 19: 4435-4446.

For research use only. Not intended for any clinical use.